Tumor Biology

, Volume 37, Issue 6, pp 7657–7665 | Cite as

Lin28A enhances chemosensitivity of colon cancer cells to 5-FU by promoting apoptosis in a let-7 independent manner

  • Tianzhen Wang
  • Peng Han
  • Yan He
  • Ci Zhao
  • Guangyu Wang
  • Weiwei Yang
  • Ming Shan
  • Yuanyuan Zhu
  • Chao Yang
  • Mingjiao Weng
  • Di Wu
  • Lin Gao
  • Xiaoming Jin
  • Yunwei Wei
  • BinBin Cui
  • Guomin Shen
  • Xiaobo Li
Original Article


RNA-binding protein Lin28A is frequently over-expressed in human malignant tumors and is associated with tumor advance and poor prognosis. However, the expression pattern and functions of Lin28A in colon cancer are unknown. In this study, we detected the expression of Lin28A in colon cancer patients and tested the effect of Lin28A on the chemotherapeutic sensitivity of colon cancer cells to 5-fluorouracil (5-FU). As expected, we showed that Lin28A is up-regulated in 73.3 % of colon cancer patients. However, to our surprise, we found that oncogenic protein Lin28A-enforced expression in colon cancer cells enhanced the chemosensitivity of cancer cells to 5-FU via promoting the cell apoptosis. Further mechanisms study revealed that the effect of Lin28A increasing chemosensitivity of cancer cells is in a let-7 independent manner, but which is associated with decreasing the expression of DNA damage repair protein H2AX. Conclusively, here we reported an unexpected function of Lin28A, which may shed lights on fully understanding the physiological and pathological roles of this oncogene.


Colon cancer Lin28A Chemosensitivity Apoptosis H2AX 



This work was supported by the National Natural Science Foundation of China (Grant No. 81302061 to Tianzhen Wang, Grant No. 81401961 to Xiaobo Li, Grant No. 81302388 to Lin Gao, and Grant No. 31301076 to Guomin Shen), Postdoctoral Scientific Research Development Fund of Heilongjiang Province (Grant No. LBH-Q14104 to Xiaobo Li), and Wu-Lian-De Youth Science Foundation of Harbin Medical University (Grant No.WLD-QN1411 to Xiaobo Li).


  1. 1.
    Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010;127(12):2893–917. doi: 10.1002/ijc.25516.CrossRefPubMedGoogle Scholar
  2. 2.
    Ambros V, Horvitz HR. Heterochronic mutants of the nematode Caenorhabditis elegans. Science (New York, NY). 1984;226(4673):409–16.CrossRefGoogle Scholar
  3. 3.
    Moss EG, Lee RC, Ambros V. The cold shock domain protein Lin-28 controls developmental timing in C. elegans and is regulated by the Lin-4 RNA. Cell. 1997;88(5):637–46.CrossRefPubMedGoogle Scholar
  4. 4.
    Reinhart BJ, Slack FJ, Basson M, Pasquinelli AE, Bettinger JC, Rougvie AE, et al. The 21-nucleotide let-7 RNA regulates developmental timing in Caenorhabditis elegans. Nature. 2000;403(6772):901–6. doi: 10.1038/35002607.CrossRefPubMedGoogle Scholar
  5. 5.
    Moss EG, Tang L. Conservation of the heterochronic regulator Lin-28, its developmental expression and microRNA complementary sites. Dev Biol. 2003;258(2):432–42.CrossRefPubMedGoogle Scholar
  6. 6.
    Darr H, Benvenisty N. Genetic analysis of the role of the reprogramming gene LIN-28 in human embryonic stem cells. Stem Cells (Dayton, Ohio). 2009;27(2):352–62. doi: 10.1634/stemcells.2008-0720.CrossRefGoogle Scholar
  7. 7.
    Yu J, Vodyanik MA, Smuga-Otto K, Antosiewicz-Bourget J, Frane JL, Tian S, et al. Induced pluripotent stem cell lines derived from human somatic cells. Science (New York, NY). 2007;318(5858):1917–20. doi: 10.1126/science.1151526.CrossRefGoogle Scholar
  8. 8.
    Li X, Zhang J, Gao L, McClellan S, Finan MA, Butler TW, et al. MiR-181 mediates cell differentiation by interrupting the Lin28 and let-7 feedback circuit. Cell Death Differ. 2012;19(3):378–86. doi: 10.1038/cdd.2011.127.CrossRefPubMedGoogle Scholar
  9. 9.
    Thornton JE, Gregory RI. How does Lin28 let-7 control development and disease? Trends Cell Biol. 2012;22(9):474–82. doi: 10.1016/j.tcb.2012.06.001.CrossRefPubMedPubMedCentralGoogle Scholar
  10. 10.
    King CE, Cuatrecasas M, Castells A, Sepulveda AR, Lee JS, Rustgi AK. Lin28B promotes colon cancer progression and metastasis. Cancer Res. 2011;71(12):4260–8. doi: 10.1158/0008-5472.can-10-4637.CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    Hamano R, Miyata H, Yamasaki M, Sugimura K, Tanaka K, Kurokawa Y, et al. High expression of Lin28 is associated with tumour aggressiveness and poor prognosis of patients in oesophagus cancer. Br J Cancer. 2012;106(8):1415–23. doi: 10.1038/bjc.2012.90.CrossRefPubMedPubMedCentralGoogle Scholar
  12. 12.
    Tummala R, Nadiminty N, Lou W, Zhu Y, Gandour-Edwards R, Chen HW, et al. Lin28 promotes growth of prostate cancer cells and activates the androgen receptor. Am J Pathol. 2013;183(1):288–95. doi: 10.1016/j.ajpath.2013.03.011.CrossRefPubMedPubMedCentralGoogle Scholar
  13. 13.
    Wang T, Wang G, Hao D, Liu X, Wang D, Ning N, et al. Aberrant regulation of the Lin28A/Lin28B and let-7 loop in human malignant tumors and its effects on the hallmarks of cancer. Mol Cancer. 2015;14:125. doi: 10.1186/s12943-015-0402-5.CrossRefPubMedPubMedCentralGoogle Scholar
  14. 14.
    Pang M, Wu G, Hou X, Hou N, Liang L, Jia G, et al. Lin28B promotes colon cancer migration and recurrence. PLoS One. 2014;9(10):e109169. doi: 10.1371/journal.pone.0109169.CrossRefPubMedPubMedCentralGoogle Scholar
  15. 15.
    King CE, Wang L, Winograd R, Madison BB, Mongroo PS, Johnstone CN, et al. Lin28B fosters colon cancer migration, invasion and transformation through let-7-dependent and -independent mechanisms. Oncogene. 2011;30(40):4185–93. doi: 10.1038/onc.2011.131.CrossRefPubMedPubMedCentralGoogle Scholar
  16. 16.
    Malik F, Korkaya H, Clouthier SG, Wicha MS. Lin28 and HER2: two stem cell regulators conspire to drive aggressive breast cancer. Cell Cycle (Georgetown, Tex). 2012;11(15):2780–1. doi: 10.4161/cc.21395.CrossRefGoogle Scholar
  17. 17.
    Viswanathan SR, Powers JT, Einhorn W, Hoshida Y, Ng TL, Toffanin S, et al. Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet. 2009;41(7):843–8. doi: 10.1038/ng.392.CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    Teng RY, Zhou JC, Jiang ZN, Xu CY, Li ZD, Wang QC, et al. The relationship between Lin28 and the chemotherapy response of gastric cancer. Onco Targets Ther. 2013;6:1341–5. doi: 10.2147/ott.s45705.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lv K, Liu L, Wang L, Yu J, Liu X, Cheng Y, et al. Lin28 mediates paclitaxel resistance by modulating p21, Rb and let-7a miRNA in breast cancer cells. PLoS One. 2012;7(7):e40008. doi: 10.1371/journal.pone.0040008.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Tian N, Han Z, Li Z, Zhou M, Fan C. Lin28/let-7/Bcl-xL pathway: the underlying mechanism of drug resistance in Hep3B cells. Oncol Rep. 2014;32(3):1050–6. doi: 10.3892/or.2014.3292.PubMedGoogle Scholar
  21. 21.
    Piskounova E, Viswanathan SR, Janas M, LaPierre RJ, Daley GQ, Sliz P, et al. Determinants of microRNA processing inhibition by the developmentally regulated RNA-binding protein Lin28. J Biol Chem. 2008;283(31):21310–4. doi: 10.1074/jbc.C800108200.CrossRefPubMedGoogle Scholar
  22. 22.
    Hagan JP, Piskounova E, Gregory RI. Lin28 recruits the TUTase Zcchc11 to inhibit let-7 maturation in mouse embryonic stem cells. Nat Struct Mol Biol. 2009;16(10):1021–5. doi: 10.1038/nsmb.1676.CrossRefPubMedPubMedCentralGoogle Scholar
  23. 23.
    Heo I, Joo C, Kim YK, Ha M, Yoon MJ, Cho J, et al. TUT4 in concert with Lin28 suppresses microRNA biogenesis through pre-microRNA uridylation. Cell. 2009;138(4):696–708. doi: 10.1016/j.cell.2009.08.002.CrossRefPubMedGoogle Scholar
  24. 24.
    Heo I, Joo C, Cho J, Ha M, Han J, Kim VN. Lin28 mediates the terminal uridylation of let-7 precursor microRNA. Mol Cell. 2008;32(2):276–84. doi: 10.1016/j.molcel.2008.09.014.CrossRefPubMedGoogle Scholar
  25. 25.
    Chang HM, Triboulet R, Thornton JE, Gregory RI. A role for the Perlman syndrome exonuclease Dis3l2 in the Lin28-let-7 pathway. Nature. 2013;497(7448):244–8. doi: 10.1038/nature12119.CrossRefPubMedPubMedCentralGoogle Scholar
  26. 26.
    Mullen TE, Marzluff WF. Degradation of histone mRNA requires oligouridylation followed by decapping and simultaneous degradation of the mRNA both 5′ to 3′ and 3′ to 5′. Genes Dev. 2008;22(1):50–65. doi: 10.1101/gad.1622708.CrossRefPubMedPubMedCentralGoogle Scholar
  27. 27.
    Redon C, Pilch D, Rogakou E, Sedelnikova O, Newrock K, Bonner W. Histone H2A variants H2AX and H2AZ. Curr Opin Genet Dev. 2002;12(2):162–9.CrossRefPubMedGoogle Scholar
  28. 28.
    Dickey JS, Redon CE, Nakamura AJ, Baird BJ, Sedelnikova OA, Bonner WM. H2AX: functional roles and potential applications. Chromosoma. 2009;118(6):683–92. doi: 10.1007/s00412-009-0234-4.CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    Xu K, Chen Z, Cui Y, Qin C, He Y, Song X. Combined olaparib and oxaliplatin inhibits tumor proliferation and induces G2/M arrest and gamma-H2AX foci formation in colorectal cancer. Onco Targets Ther. 2015;8:3047–54. doi: 10.2147/ott.s89154.CrossRefPubMedPubMedCentralGoogle Scholar
  30. 30.
    Srinivas US, Dyczkowski J, Beissbarth T, Gaedcke J, Mansour WY, Borgmann K, et al. 5-Fluorouracil sensitizes colorectal tumor cells towards double stranded DNA breaks by interfering with homologous recombination repair. Oncotarget. 2015;6(14):12574–86.CrossRefPubMedPubMedCentralGoogle Scholar
  31. 31.
    Adam-Zahir S, Plowman PN, Bourton EC, Sharif F, Parris CN. Increased gamma-H2AX and Rad51 DNA repair biomarker expression in human cell lines resistant to the chemotherapeutic agents nitrogen mustard and cisplatin. Chemotherapy. 2014;60(5–6):310–20. doi: 10.1159/000430086.PubMedGoogle Scholar
  32. 32.
    Kao J, Milano MT, Javaheri A, Garofalo MC, Chmura SJ, Weichselbaum RR, et al. Gamma-H2AX as a therapeutic target for improving the efficacy of radiation therapy. Curr Cancer Drug Targets. 2006;6(3):197–205.CrossRefPubMedGoogle Scholar
  33. 33.
    Taneja N, Davis M, Choy JS, Beckett MA, Singh R, Kron SJ, et al. Histone H2AX phosphorylation as a predictor of radiosensitivity and target for radiotherapy. J Biol Chem. 2004;279(3):2273–80. doi: 10.1074/jbc.M310030200.CrossRefPubMedGoogle Scholar

Copyright information

© International Society of Oncology and BioMarkers (ISOBM) 2015

Authors and Affiliations

  1. 1.Department of PathologyHarbin Medical UniversityHarbinChina
  2. 2.Department of Colorectal SurgeryThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  3. 3.Department of Gastrointestinal Medical OncologyThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  4. 4.Department of Breast SurgeryThe Affiliated Tumor Hospital of Harbin Medical UniversityHarbinChina
  5. 5.Department of Obstetrics and GynecologyFirst Affiliated Hospital of Harbin Medical UniversityHarbinChina
  6. 6.Center for Endemic Disease Control, Chinese Center for Disease Control and PreventionHarbin Medical UniversityHarbinChina
  7. 7.Department of General SurgeryThe First Affiliated Hospital of Harbin Medical UniversityHarbinChina
  8. 8.Department of Medical Genetics, Medical CollegeHenan University of Science and TechnologyLuoyangChina

Personalised recommendations